1
|
The Risk of Developing Lymphoma among Autoimmune Thyroid Disorder Patients: A Cross-Section Study. DISEASE MARKERS 2022; 2022:4354595. [PMID: 35692889 PMCID: PMC9187447 DOI: 10.1155/2022/4354595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 04/06/2022] [Accepted: 05/16/2022] [Indexed: 11/20/2022]
Abstract
Background Graves' disease (GD) and Hashimoto's thyroiditis (HT) are the most common types of autoimmune thyroid diseases (AITD), and both are characterized by the infiltration of lymphocytes into the thyroid gland. Moreover, autoimmune diseases like HT have a higher risk of developing lymphoma. This study is aimed at assessing the prevalence and association of lymphoma in patients with AITD. Methods This cross-sectional study was conducted in King Abdulaziz Medical City, Jeddah, Saudi Arabia. Data were gathered from the medical records of patients aged 18 years or older who developed AITD. A total number of 140 medical records were collected, and 72 patients were included after applying in exclusion criteria. Data on the subtype, clinical-stage, treatment modality, patient status, remission, and relapse were collected for patients who developed lymphoma. Results Among 72 patients who developed AITD, HT was diagnosed in 58 (80.6%) patients and GD in 14 (19.4%). Five (7%) patients were diagnosed with lymphoma all of whom had a history of HT. The subtypes of lymphoma were diffuse large B-cell lymphoma (DLBCL 3; 4.2%), follicular lymphoma 1 (1.4%), and Hodgkin's lymphoma 1 (1.4%). Conclusion The prevalence of PTL in patients with AITD, specifically HT, was 7%. Most patients developed NHL, with DLBCL being the most common subtype. The onset of lymphoma in this study was lower than reported in the literature. All patients with PTL had HT in their backgrounds. Further national studies are warranted to explore the relationship between the two diseases to provide more insight into the comprehension of this association.
Collapse
|
2
|
|
3
|
Wu W, Youm W, Rezk SA, Zhao X. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of 54 cases in the literature. Am J Clin Pathol 2013; 140:258-73. [PMID: 23897264 DOI: 10.1309/ajcphz3cho4huwet] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
OBJECTIVES To report a patient with primary effusion lymphoma who was negative for human herpesvirus-8 (HHV-8), human immunodeficiency virus, Epstein-Barr virus, hepatitis C virus, and hepatitis B virus, as well as review 54 reported cases of HHV-8-unrelated primary effusion lymphoma (PEL)-like lymphoma in the literature to clarify the nature of this entity. METHODS The patients' characteristics, clinical presentation, pathogenesis, morphologic-immunophenotypic features, clinical management, and prognosis were studied. RESULTS HHV-8-negative PEL-like lymphomas often occur in immunocompetent and elderly patients, are sometimes associated with chronic inflammation-related fluid overload, are mostly large B-cell or large B-cell with plasmacytic differentiation type, and are associated with a better prognosis. CONCLUSIONS In various aspects, HHV-8-unrelated PEL-like lymphoma is a different entity from HHV-8-related PEL. Immunophenotype, morphology, and c-myc/8q24 status should be included for differential diagnosis. A test for c-myc or 8q24 abnormalities should be recommended for subdividing HHV-8-unrelated PEL-like lymphoma, which may have benefits in patient management.
Collapse
Affiliation(s)
- William Wu
- Department of Pathology and Laboratory Medicine, University of California, Irvine
| | - Wonita Youm
- Department of Pathology and Laboratory Medicine, University of California, Irvine
| | - Sherif A. Rezk
- Department of Pathology and Laboratory Medicine, University of California, Irvine
| | - Xiaohui Zhao
- Department of Pathology and Laboratory Medicine, University of California, Irvine
| |
Collapse
|
4
|
iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma. PLoS One 2012; 7:e42635. [PMID: 22880059 PMCID: PMC3413636 DOI: 10.1371/journal.pone.0042635] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Accepted: 07/10/2012] [Indexed: 02/06/2023] Open
Abstract
The T cell response to B cell lymphomas differs from the majority of solid tumors in that the malignant cells themselves are derived from B lymphocytes, key players in immune response. B cell lymphomas are therefore well situated to manipulate their surrounding microenvironment to enhance tumor growth and minimize anti-tumor T cell responses. We analyzed the effect of T cells on the growth of a transplantable B cell lymphoma and found that iNKT cells suppressed the anti-tumor CD8+ T cell response. Lymphoma cells transplanted into syngeneic wild type (WT) mice or Jalpha18−/− mice that specifically lack iNKT cells grew initially at the same rate, but only the mice lacking iNKT cells were able to reject the lymphoma. This effect was due to the enhanced activity of tumor-specific CD8+ T cells in the absence of iNKT cells, and could be partially reversed by reconstitution of iNKT cells in Jalpha 18−/− mice. Treatment of tumor-bearing WT mice with alpha -galactosyl ceramide, an activating ligand for iNKT cells, reduced the number of tumor-specific CD8+ T cells. In contrast, lymphoma growth in CD1d1−/− mice that lack both iNKT and type II NKT cells was similar to that in WT mice, suggesting that type II NKT cells are required for full activation of the anti-tumor immune response. This study reveals a tumor-promoting role for iNKT cells and suggests their capacity to inhibit the CD8+ T cell response to B cell lymphoma by opposing the effects of type II NKT cells.
Collapse
|
5
|
Mäkelä KT, Visuri T, Pulkkinen P, Eskelinen A, Remes V, Virolainen P, Junnila M, Pukkala E. Risk of cancer with metal-on-metal hip replacements: population based study. BMJ 2012; 345:e4646. [PMID: 22833626 PMCID: PMC3404595 DOI: 10.1136/bmj.e4646] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/15/2012] [Indexed: 12/12/2022]
Abstract
OBJECTIVE To assess the risk of cancer associated with modern primary metal-on-metal hip replacements. DESIGN Population based study. SETTING Nationwide retrospective comparative register. PARTICIPANTS 10,728 patients who underwent metal-on-metal total hip arthroplasty and 18,235 patients who underwent conventional metal-on-polyethylene, ceramic-on-polyethylene, and ceramic-on-ceramic total hip arthroplasty (the non-metal-on-metal cohort) in the Finnish Arthroplasty Register 2001-10. Data on cancer cases up to 2010 for these cohorts were extracted from the Finnish Cancer Registry. MAIN OUTCOME MEASURES The relative risk of cancer was expressed as the ratio of observed to expected number of cases from the Finnish population--that is, the standardised incidence ratio. The relative risk of cancer in the metal-on-metal cohort compared with the non-metal-on-metal cohort was estimated with analyses of these ratios and Poisson regression. RESULTS The overall risk of cancer in patients with metal-on-metal hip implants was similar to that in the Finnish population (378 observed v 400 expected, standardised incidence ratio 0.95, 95% confidence interval 0.85 to 1.04). The overall risk of cancer in patients with metal-on-metal hip implants was also no higher than in patients who had received non-metal-on-metal hip implants (relative risk 0.92, 0.81 to 1.05). CONCLUSIONS Metal-on-metal hip replacements are not associated with an increased overall risk of cancer during a mean follow-up of four years.
Collapse
Affiliation(s)
- Keijo T Mäkelä
- Department of Orthopaedics and Traumatology, Surgical Hospital, Turku University Hospital, FI-20701 Turku, Finland.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
The risk of lymphoma, particularly non-Hodgkin's lymphoma, is an important concern associated with therapy for inflammatory bowel disease (IBD). Lymphoma risks have been described for nearly all immunomodulatory therapies for IBD, and it is therefore important to have discussions with patients before initiating therapy. However, it is also important to put risks into contexts that IBD patients can appropriately appreciate. Relative risks can appear large for these medications, while, by contrast, the absolute risk may be quite low. Additionally, understanding the risks of foregoing immunomodulatory therapy--specifically, continued active disease and/or continued corticosteroid use--can frame an appropriate risk-benefit discussion for both patients and physicians.
Collapse
|
7
|
Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The care of inflammatory bowel disease has changed considerably with the introduction of a number of immunosuppressants including anti-metabolite and anti-TNF therapies. While efficacious, these medications also carry important risks, notably the potential risk of lymphoma. This risk is one of the most worrisome for both patients and physicians. Our current knowledge is still evolving; however, our understanding of what risks these drugs carry, both individually and synergistically, is critical in allowing informed decision making. In this article, we will describe the known lymphoma risks of commonly used immunosuppressant medications in inflammatory bowel disease, with an emphasis on non-Hodgkin's lymphoma and hepatosplenic T-cell lymphoma.
Collapse
Affiliation(s)
- Meenakshi Bewtra
- Division of Gastroenterology, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
| | | |
Collapse
|
8
|
Abstract
This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients.
Collapse
Affiliation(s)
- Meenakshi Bewtra
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
| | | |
Collapse
|
9
|
Abstract
This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients.
Collapse
Affiliation(s)
- Meenakshi Bewtra
- Division of Gastroenterology, Department of Medicine, University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
10
|
Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009; 33:255-9. [PMID: 19800763 DOI: 10.1016/j.jaut.2009.09.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Bone marrow transplantation has been adoptively transferred from oncology to the treatment of autoimmune disorders. Along with extension of prevalent transplant-related concepts, the assumed mechanism that arrests autoimmunity involves elimination of pathogenic cells and resetting of immune homeostasis. Similar to graft versus tumor (GVT) reactivity, allogeneic transplants are considered to provide a better platform of immunomodulation to induce a graft versus autoimmunity reaction (GVA). It is yet unclear whether recurrence of autoimmunity in both autologous and allogeneic settings reflects relapse of the disease, transplant-associated immune dysfunction or insufficient immune modulation. Possible causes of disease recurrence include reactivation of residual host pathogenic cells and persistence of memory cells, genetic predisposition to autoimmunity and pro-inflammatory characteristics of the target tissues. Most important, there is little evidence that autoimmune disorders are indeed abrogated by current transplant procedures, despite reinstitution of both peripheral and thymic immune homeostasis. It is postulated that non-specific immunosuppressive therapy that precedes and accompanies current bone marrow transplant strategies is detrimental to the active immune process that restores self-tolerance. This proposition refocuses the need to develop strategies of immunomodulation without immunosuppression.
Collapse
Affiliation(s)
- Isaac Yaniv
- Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel
| | | | | | | | | |
Collapse
|
11
|
Novel Isolated Cerebral ALλ Amyloid Angiopathy With Widespread Subcortical Distribution and Leukoencephalopathy Due to Atypical Monoclonal Plasma Cell Proliferation, and Terminal Systemic Gammopathy. J Neuropathol Exp Neurol 2009; 68:286-99. [DOI: 10.1097/nen.0b013e31819a87f9] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
|
12
|
The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 2008; 6:e152. [PMID: 18578569 PMCID: PMC2435152 DOI: 10.1371/journal.pbio.0060152] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2008] [Accepted: 05/13/2008] [Indexed: 11/19/2022] Open
Abstract
A variety of circumstantial evidence from humans has implicated the B cell antigen receptor (BCR) in the genesis of B cell lymphomas. We generated mouse models designed to test this possibility directly, and we found that both the constitutive and antigen-stimulated state of a clonal BCR affected the rate and outcome of lymphomagenesis initiated by the proto-oncogene MYC. The tumors that arose in the presence of constitutive BCR differed from those initiated by MYC alone and resembled chronic B cell lymphocytic leukemia/lymphoma (B-CLL), whereas those that arose in response to antigen stimulation resembled large B-cell lymphomas, particularly Burkitt lymphoma (BL). We linked the genesis of the BL-like tumors to antigen stimulus in three ways. First, in reconstruction experiments, stimulation of B cells by an autoantigen in the presence of overexpressed MYC gave rise to BL-like tumors that were, in turn, dependent on both MYC and the antigen for survival and proliferation. Second, genetic disruption of the pathway that mediates signaling from the BCR promptly killed cells of the BL-like tumors as well as the tumors resembling B-CLL. And third, growth of the murine BL could be inhibited by any of three distinctive immunosuppressants, in accord with the dependence of the tumors on antigen-induced signaling. Together, our results provide direct evidence that antigenic stimulation can participate in lymphomagenesis, point to a potential role for the constitutive BCR as well, and sustain the view that the constitutive BCR gives rise to signals different from those elicited by antigen. The mouse models described here should be useful in exploring further the pathogenesis of lymphomas, and in preclinical testing of new therapeutics. It has long been suspected that the malignant proliferation of B lymphocytes known as lymphomas might represent a perversion of how the cells normally respond to antigen. In particular, the molecular receptor on the surface of the cells that signals the presence of antigen might be abnormally active in lymphomas. We have tested this hypothesis by engineering the genome of mice so that virtually all of the B cells are commandeered by a single version of the surface receptor, then stimulated that receptor with the molecule it is designed to recognize. Our results indicate that both the unstimulated and stimulated states of the receptor can cooperate with an oncogene known as MYC in the genesis of lymphomas. But the two states of the receptor give rise to different forms of lymphoma. In particular, the stimulated form cooperates with MYC to produce a disease that closely resembles Burkitt lymphoma. These results illuminate the mechanisms that are responsible for lymphomas and could inform the development of new strategies to treat the disease. A series of genetically engineered mice were used to substantiate a long-standing speculation that chronic immune-stimulus may be involved in the genesis of certain lymphomas, illuminating the pathogenesis of B cell lymphomas and suggesting new strategies to treat several forms of this malignancy, including Burkitt lymphoma.
Collapse
|
13
|
Onega T, Baron J, MacKenzie T. Cancer after Total Joint Arthroplasty: A Meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1532-7. [PMID: 16896045 DOI: 10.1158/1055-9965.epi-06-0127] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Some epidemiologic and laboratory studies have suggested that total joint arthroplasty could increase the risk of cancer. In this meta-analysis, we attempt to clarify the association of joint arthroplasty with subsequent cancer incidence. METHODS We identified population-based studies reporting standardized incidence ratios (SIR) for cancer following large joint arthroplasty. After summing the observed and expected numbers of cases across all qualifying studies, we calculated SIRs for all cancers, and for those at 28 anatomic sites. Latency analysis involving 175,166 patients characterized short-term and long-term cancer associations. RESULTS The analyses included 1,435,356 person-years of follow-up and 20,045 cases of cancer. Overall cancer risk among patients with arthroplasty was equal to that for the general population. The relative risk of lung cancer, reduced in the first 5 years after arthroplasty, increased significantly over time to approach that of the general population. Risks for all sites in the luminal gastrointestinal tract were significantly reduced by 10% to 20%; with relative risks that were generally stable over time. Increased risks were seen for cancer of the prostate (SIR, 1.12; 95% confidence interval, 1.08-1.16); similar relative risks were seen in each time period after the procedure. For melanoma, relative risks increased with follow-up to a SIR of 1.43 (95% confidence interval, 1.13-1.79) for 10 or more years after arthroplasty. There was a similar delayed emergence of increased risks for cancers of the urinary tract and oropharynx. The relative risk for bone cancer decreased with time after the procedure. CONCLUSIONS There does not seem to be an overall increased risk of cancer following total joint arthroplasty. Although the risks of prostate cancer and melanoma seem to be elevated, there is no obvious mechanism for these associations. Reductions in risk for some malignancies may not be causal.
Collapse
Affiliation(s)
- Tracy Onega
- Department of Medicine, Dartmouth Medical School, Evergreen Center, Suite 300, 46 Centerra Parkway, Lebanon, NH 03756, USA
| | | | | |
Collapse
|
14
|
McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2003; 25:913-27. [PMID: 12381213 DOI: 10.2165/00002018-200225130-00003] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Psoriasis is a chronic, debilitating skin condition that affects millions of people and is attributed to both genetic and environmental factors. Topical therapy is generally considered to be the first-line treatment of psoriasis. However, many patients do not respond to topical therapy or have disease so extensive that topical therapy is not practical. For these patients, systemic therapy is indicated. Presently, there are four available systemic treatments, psoralen with ultraviolet A (PUVA), methotrexate, oral retinoids (acitretin), and cyclosporin. Unfortunately, all of these treatments have significant potential adverse effects. PUVA may acutely cause nausea, pruritus and sunburn. More chronic and concerning is the development of PUVA lentigines, ocular complications and skin cancer. Non-melanoma skin cancer has been directly linked to PUVA; however, the association with melonoma is more elusive. Methotrexate use most notably carries the risk of hepatic fibrosis and cirrhosis, which is not always evident on liver function tests. Other more rare, but potentially life-threatening adverse effects include pancytopenia, lymphoproliferative disorders and acute pneumonitis. The addition of folic acid may help to reduce the risk of increasing liver enzymes and haematological toxicity seen in those taking methotrexate. Both methotrexate and oral retinoids are teratogenic and should never be used in pregnancy. Oral retinoids are probably the least effective available systemic medication for the treatment of plaque psoriasis. The effects are improved with the addition of other systemic therapies. Acitretin has replaced the formerly used etretinate primarily because of the significantly shorter half-life. The adverse effects are generally mild and reversible, making the drug fairly safe for long-term use. The most commonly seen adverse effects include elevated serum lipids, generalised xerosis and alopecia. Bony abnormalities, while somewhat controversial, have also been described and include diffuse idiopathic skeletal hyperostosis, skeletal calcifications and osteoporosis. Cyclosporin is the most recently approved systemic medication for plaque psoriasis. The nephrotoxicity associated with the use of cyclosporin can be minimised when used in lower doses and for a limited duration. Hypertension is usually mild and can be seen in up to about one-third of patients receiving long-term therapy. Cutaneous and internal malignancies have also been reported with cyclosporin and tend to be correlated with duration of treatment. In this review, we will examine the potential adverse effects with these US Food and Drug Administration-approved treatments in adults, with specific emphasis on the controversies that surround long-term therapy with these agents and their cumulative adverse effects.
Collapse
Affiliation(s)
- Stacy L McClure
- Department of Dermatology, Northwestern University Medical School, Chicago, Illinois 60611, USA
| | | | | |
Collapse
|
15
|
Paavolainen P, Pukkala E, Pulkkinen P, Visuri T. Causes of death after total hip arthroplasty: a nationwide cohort study with 24,638 patients. J Arthroplasty 2002; 17:274-81. [PMID: 11938501 DOI: 10.1054/arth.2002.30774] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Based on the nationwide registration of the total hip arthroplasties (THAs) in Finland since 1980, a cohort of 24,638 patients with primary THA was gathered and followed for causes of death until December 31, 1996. The causes of death were divided into 20 main categories according to the classification of diseases ICD-10. The number of person-years was 153,410, and the mean length of follow-up of a person was 6.2 years. During the follow-up, 4,626 patients died; the expected number was 6,746. The standardized mortality ratio (SMR) was 0.69 (95% confidence interval; 0.67-0.70), without any difference between men and women. The total risk increased during the follow-up, with the highest being 0.84 (95% confidence interval, 0.81-0.87). Among the ICD categories, there were significantly low SMRs for cancers (0.54), accidents (0.74), cardiovascular diseases (0.70), and respiratory diseases (0.46). Among the diseases, there was a constant and significant decline of the SMR for dementia and Alzheimer's disease (0.50), diabetes (0.40), myocardial infarction (0.73), hypertension (0.68), other ischemic diseases (0.70), other heart diseases (0.57), and cerebrovascular diseases (0.70). The explanation for the decreased SMRs seems to be attributed to factors other than the THA per se, such as preoperative patient selection, more active lifestyle after THA, and possibly the use of anti-inflammatory drugs.
Collapse
Affiliation(s)
- Pekka Paavolainen
- Division of Orthopaedic Surgery, Surgical Hospital, University Central Hospital, and National Agency for Medicines, Helsinki, Finland.
| | | | | | | |
Collapse
|
16
|
Affiliation(s)
- I R Mackay
- Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3168, Australia
| | | |
Collapse
|
17
|
Abstract
SLE susceptibility requires the interplay of an unknown number of genes and equally unidentified triggering events. The past few years have seen significant advances in our understanding of SLE susceptibility through the genetic analysis of murine models. The NZM2410 strain, which is derived from the NZB/WF1 model has played a significant role in these advances. The main advantages presented by this strain over other models are the genetic homozygozity at all loci and an highly penetrant early onset lupus nephritis in both males and females, indicating that the strongest BWF1 susceptibility loci were retained in NZM2410. After identification of NZM2410 susceptibility loci via linkage analyses, congenic strains have been derived in order to convert a polygenic system into a series of monogenic traits. These congenic strains have been analyzed in an integrated process which has provided simultaneously 1) novel functional characterization of the Sle susceptibility loci, 2) high resolution genetic maps that will lead to the identification of the corresponding susceptibility genes by either candidate locus or positional cloning, and 3) insights into the mechanisms by which these loci interact to produce systemic autoimmunity with fatal end-organ damage.
Collapse
Affiliation(s)
- L Morel
- Department of Medicine, University of Florida, Gainesville 32610-0275, USA.
| | | |
Collapse
|
18
|
Greiner A, Knörr C, Seeberger H, Schultz A, Müller-Hermelink HK. Tumor biology of mucosa-associated lymphoid tissue lymphomas. Recent Results Cancer Res 2000; 156:19-26. [PMID: 10802859 DOI: 10.1007/978-3-642-57054-4_3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Extranodal lymphomas arising at mucosal sites exhibit clinicopathological features that suggest a closer relationship of these tumors to the structure and function of mucosa-associated lymphoid tissue (MALT) than to lymph nodes. The factors that induce MALT in these tissues are operative in early MALT lymphoma development and the progressive independence on T-cell help defines late stages of MALT lymphoma genesis.
Collapse
Affiliation(s)
- A Greiner
- Institut für Pathologie, Universität Würzburg, Germany
| | | | | | | | | |
Collapse
|
19
|
Paavolainen P, Pukkala E, Pulkkinen P, Visuri T. Cancer incidence after total knee arthroplasty: a nationwide Finnish cohort from 1980 to 1996 involving 9,444 patients. ACTA ORTHOPAEDICA SCANDINAVICA 1999; 70:609-17. [PMID: 10665728 DOI: 10.3109/17453679908997851] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
A nationwide, computer-based survey of all total joint arthroplasties performed in Finland has been carried out since January 1980. From these records, a cohort of 9,444 patients, with 51,756 person-years, after primary operation with a total polyethylene-on-metal knee arthroplasty (TKA) was followed up for cancer through the Finnish Cancer Register up to December 31, 1996. During the follow-up, 706 cancers were observed. The expected number, based on national rates, was 719; therefore, the standardized incidence ratio (SIR) for all cancers was 0.98. The SIRs for non-Hodgkin's lymphoma (1.40), Hodgkin's disease (1.24) and multiple myeloma (1.54) were increased, but only that of non-Hodgkin's lymphoma was statistically significant 3-10 years after the operation. The numbers of observed cases of prostate cancer exceeded that of expected, with a SIR value of 1.49. A low SIR of lung cancer was observed among men, especially during the first 3 years (0.61), but not in women. The SIR for colon cancer was below unity in women only (SIR 0.70). The SIR for cancer of the urinary organs was close to unity (0.97). SIR relating to soft tissue and bone cancer did not differ significantly from unity, and none of the 6 sarcomas was observed at the site of a prosthesis. The overall cancer risk after TKA done for primary osteoarthrosis seems not to be increased. The increases in lymphoma and prostate cancer risk, however, are observations that could be related to TKA and justify further follow-up of the cohort.
Collapse
Affiliation(s)
- P Paavolainen
- The Jorvi Hospital, Department of Surgery and National Agency for Medicines, Espoo, Finland.
| | | | | | | |
Collapse
|
20
|
Hasegawa Y, Itoh T, Tamagawa Y, Komeno T, Kojima H, Ninomiya H, Yatabe Y, Mori N, Nagasawa T. Non-Hodgkin's lymphoma followed by plasmacytoma, both arising in A thyroid gland with Hashimoto's disease. Leuk Lymphoma 1999; 35:613-8. [PMID: 10609800 DOI: 10.1080/10428199909169627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
We describe here a rare case of malignant lymphoma followed by plasmacytoma in Hashimoto's thyroiditis. The patient developed malignant lymphoma (small, non-cleaved cell, and non Burkitt's type by Working Formulation classification), and remained in remission for 2 years after receiving combination chemotherapy, and then developed plasmacytoma in the same lesion. Rearrangement bands for IgH from both specimens showed different bands, indicating that both were of monoclonal type but of a different clonal origin. Considering the clinical course in this case, thyroidectomy may be indicated for lymphoproliferative diseases in Hashimoto's thyroiditis treated with chemotherapy.
Collapse
Affiliation(s)
- Y Hasegawa
- Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Paavolainen P, Pukkala E, Pulkkinen P, Visuri T. Cancer incidence in Finnish hip replacement patients from 1980 to 1995: a nationwide cohort study involving 31,651 patients. J Arthroplasty 1999; 14:272-80. [PMID: 10220179 DOI: 10.1016/s0883-5403(99)90051-7] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Nationwide, computer-based reporting of all arthroplasties performed in Finland was started in January 1980. Using data from these records, a cohort of 31,651 polyethylene-on-metal total hip arthroplasty (THA) patients was followed up for cancer, using Finnish Cancer Registry data, from 1980 to 1995. During follow-up, 2,367 cancers were observed. There were statistically significantly fewer cancers among the THA patients (standardized incidence ratio [SIR], 0.90; 95% confidence interval [CI], 0.87-0.93). SIRs for cancers of the lung (0.69) and stomach (0.77) were significantly below unity. There was no significantly increased risk at any site. The SIR for cancer overall in male THA patients was below unity during the first 3 years after THA but returned to unity thereafter. The low SIR among men during the first 3 years was largely because the lung cancer SIR was 0.47 (95% CI, 0.35-0.62). In women, the SIR remained around 0.93 throughout follow-up. The SIR for stomach cancer was below unity only in women (SIR, 0.67; 95% CI, 0.51-0.86). For cancer of the urinary bladder, the SIR during the first 3 years after THA was below unity but later slightly above it (SIR, 1.24 in relation to > or =3 years of follow-up; 95% CI, 0.99-1.52). For myeloma and leukemia, SIRs were greater than unity only for THA patients followed up for 3 to 9 years. The study findings, in contrast to previously reported findings, do not indicate that there is any increased risk of hematopoietic cancers after THA using polyethylene-on-metal prostheses. SIRs relating to soft tissue cancers and bone sarcomas did not differ significantly from unity. No sarcoma was observed at the site of a prosthesis. THA seems to play no major role in cancer causation.
Collapse
Affiliation(s)
- P Paavolainen
- National Agency for Medicines, and the Department of Surgery, The Jorvi Hospital, Espoo, Finland
| | | | | | | |
Collapse
|
22
|
Vrethem M, Davidsson L, Bak J. Intracerebral malignant lymphoma in a patient with long-standing multiple sclerosis. Eur J Neurol 1998; 5:507-510. [PMID: 10210882 DOI: 10.1046/j.1468-1331.1998.550507.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We present a patient with long-standing MS who developed a malignant intracerebral lymphoma, suspected on MRI and verified by brain biopsy. This raises the interesting question about whether the coexistence of the two conditions is explained by cause or is just coincidental. Our case report also illustrates that other pathological conditions may develop in MS patients and demand attention in the individual patient. Copyright 1998 Lippincott Williams & Wilkins
Collapse
Affiliation(s)
- M Vrethem
- Department of Neurology, University Hospital, S-581 85, Linkoping, Sweden
| | | | | |
Collapse
|
23
|
Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 1998; 17:195-201. [PMID: 9694051 DOI: 10.1007/bf01451046] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Connective tissue diseases (CTDs) are chronic multisystemic inflammatory disorders whose indicative signs or symptoms have a high sensitivity but poor specificity in predicting the evolution into a given CTD. We have analysed 84 consecutive patients initially diagnosed as having an early undifferentiated CTD (early UCTD) with the aim of verifying the evolution into one definite CTD and of evaluating the predictive value of clinical and laboratory parameters. During a 5-year study period, 33 patients developed signs of a full-blown CTD; the highest probability of evolution was in the first 48 months after the onset. Multivariate analysis allowed us to select those variables correlating with evolution into a particular CTD, such as sclerodactyly and oesophageal dysfunction for systemic sclerosis, xerostomia and anti-nuclear antibodies (SS-A pattern) for Sjögren's syndrome, and fever and anti-DNA antibodies for systemic lupus erythematosus. Furthermore, we assessed the prevalence of various clinical and laboratory manifestations, complications and prognosis of those patients diagnosed after a 5-year disease duration period as having a UCTD. In our series, major organs such as the kidney or heart seem to be spared, whereas we detected a relatively high prevalence of endocrine disease of autoimmune origin.
Collapse
Affiliation(s)
- M G Danieli
- Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Torrette di Ancona, Italy.
| | | | | | | | | |
Collapse
|
24
|
Decker P, Briand JP, de Murcia G, Pero RW, Isenberg DA, Muller S. Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. ARTHRITIS AND RHEUMATISM 1998; 41:918-26. [PMID: 9588745 DOI: 10.1002/1529-0131(199805)41:5<918::aid-art20>3.0.co;2-w] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To characterize autoantibody response to poly(ADP-ribose) polymerase (PARP) and to assess the significance of autoantibodies to the 2 zinc fingers of this enzyme in patients with autoimmune rheumatic and bowel diseases. METHODS The specificity of antienzyme autoantibodies was established by dot immunoassay with recombinant human PARP and by enzyme-linked immunosorbent assay using the recombinant N-terminal fragment containing the DNA binding domain of PARP, the recombinant C-terminal catalytic domain (40-kd fragment), a peptide containing the nuclear localization signal (NLS) of PARP, 2 synthetic peptides (and mutated peptides) corresponding to zinc-finger motifs F1 and F2 that are present in the DNA binding domain, zinc fingers from other self antigens (e.g., peptides from Ro60, Ro52, and U1C proteins), and poly(ADP-ribose). Sera from patients with autoimmune rheumatic and bowel diseases were tested, as were affinity-purified antibodies. Histocompatibility typing of systemic lupus erythematosus (SLE) patients was performed by serology. RESULTS Antibodies from the patient sera reacted only weakly with the recombinant N- and C-terminal domains and with the NLS peptide. In contrast, the 2 synthetic peptides corresponding to zinc-finger motifs F1 and F2 represented immunodominant targets for IgG antibodies from patients with SLE, mixed connective tissue disease (MCTD), Crohn's disease, and ulcerative colitis. The sera from patients with SLE and MCTD showed much weaker reactivity with mutant peptides F1 and F2, which contain mutations at the cysteine residues involved in zinc coordination. F1/F2 antibodies did not cross-react with zinc fingers from other self proteins. No correlation was found between the presence of F1/F2 autoantibodies in SLE sera and the presence of other autoantibodies typical of this disease (e.g., anti-double-stranded DNA and poly[ADP-ribose] antibodies). The presence of F2 antibodies in the serum of SLE patients was negatively associated with HLA-DR6. CONCLUSION An autoimmune response to PARP is potentially important because this enzyme is involved in DNA repair and is rapidly cleaved during the "execution phase" of apoptosis. The high prevalence in certain autoimmune rheumatic and bowel diseases of antibodies to F1 and F2, which are directly involved in this process, is further evidence implicating involvement of the DNA repair system in chronic inflammatory diseases.
Collapse
Affiliation(s)
- P Decker
- Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
| | | | | | | | | | | |
Collapse
|
25
|
Yokose T, Kodama T, Matsuno Y, Shimosato Y, Nishimura M, Mukai K. Low-grade B cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with rheumatoid arthritis. Pathol Int 1998; 48:74-81. [PMID: 9589469 DOI: 10.1111/j.1440-1827.1998.tb03832.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The majority of thymic lymphomas are either lymphoblastic lymphoma, large B cell lymphoma or Hodgkin's disease, and other types of non-Hodgkin lymphoma are rare. A case of low-grade B cell lymphoma of mucosa-associated lymphoid tissue (MALT) in the thymus is reported. A 55-year-old Japanese female with a history of rheumatoid arthritis (RA) complained of back pain. A mediastinal tumor was identified by computerized tomography and magnetic resonance imaging, and the thymus was resected through median sternotomy. The solid and nodular tumor had several small satellite extensions and was completely confined to within the thymus. Histologically, monotonous medium-sized centrocyte-like cells occupied the medulla of the thymus and infiltrated Hassall's corpuscles (lymphoepithelial lesions). Immunohistochemically, tumor cells were positive for CD20 and CD79a. IgA and kappa light chain restriction were also found in plasmacytoid cells in the tumor. Clonal rearrangement of the immunoglobulin heavy chain gene was demonstrated by polymerase chain reaction. This case was diagnosed as MALT-type low-grade B cell lymphoma in the thymus. This is the first report of low-grade B cell lymphoma in the thymus associated with RA. As autoimmune diseases are known to be associated with lymphoid neoplasms, it is suggested that the RA played an important role in the development of malignant lymphoma in this case.
Collapse
MESH Headings
- Antigens, CD20/metabolism
- Arthritis, Rheumatoid/complications
- Arthritis, Rheumatoid/metabolism
- Arthritis, Rheumatoid/pathology
- Biomarkers, Tumor/metabolism
- Blotting, Southern
- Clone Cells/chemistry
- Female
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin kappa-Chains/metabolism
- Immunohistochemistry
- Keratins/metabolism
- Lymphoma, B-Cell, Marginal Zone/complications
- Lymphoma, B-Cell, Marginal Zone/genetics
- Lymphoma, B-Cell, Marginal Zone/metabolism
- Lymphoma, B-Cell, Marginal Zone/pathology
- Middle Aged
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Thymus Neoplasms/complications
- Thymus Neoplasms/genetics
- Thymus Neoplasms/metabolism
- Thymus Neoplasms/pathology
Collapse
Affiliation(s)
- T Yokose
- Pathology Division, National Cancer Center Research Institute East, Chiba, Japan.
| | | | | | | | | | | |
Collapse
|
26
|
Levy Y, George J, Abraham A, Afek A, Livneh A, Shoenfeld Y. Subcutaneous T-cell lymphoma in a patient with rheumatoid arthritis not treated with cytotoxic agents. Clin Rheumatol 1997; 16:606-8. [PMID: 9456013 DOI: 10.1007/bf02247801] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
This case report describes an 81-year-old patient with prolonged rheumatoid arthritis (RA), which was complicated by the occurrence of a subcutaneous T-cell lymphoma. During the course of his illness the patient had not been treated with disease-modifying agents (i.e. cytotoxic agents), but only symptomatically with anti-inflammatory drugs. This finding demonstrates a previously undescribed association between RA and a rare from of subcutaneous T-cell lymphoma, which may add more information to the controversial issue of emergence of malignancy in RA.
Collapse
Affiliation(s)
- Y Levy
- The Department of Medicine B, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Hashomer, Israel
| | | | | | | | | | | |
Collapse
|
27
|
Magro CM, Crowson AN, Harrist TJ. Atypical lymphoid infiltrates arising in cutaneous lesions of connective tissue disease. Am J Dermatopathol 1997; 19:446-55. [PMID: 9335237 DOI: 10.1097/00000372-199710000-00003] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Atypical lymphoid infiltrates occurring in the setting of connective-tissue disease (CTD) comprise malignant neoplasms of B-cell or T-cell phenotypes and various reactive lymphoid hyperplasias, such as myoepithelial sialadenitis, lymphocytic thyroiditis, and lymphocytic interstitial pneumonitis. We describe 17 patients with atypical lymphoid infiltrates arising in cutaneous lesions of CTD, the spectrum of which included lupus erythematosus, dermatomyositis, relapsing polychondritis, and lichen sclerosus et atrophicus. There were two principal categories, pseudolymphoma and malignant lymphoma, the former representing 15 of the 17 cases. The clinical and histologic features and possible pathogenetic mechanisms are discussed.
Collapse
Affiliation(s)
- C M Magro
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School Pathology Services, Inc., Cambridge, Massachusetts, USA
| | | | | |
Collapse
|
28
|
Pimentel M, Johnston JB, Allan DR, Greenberg H, Bernstein CN. Primary adrenal lymphoma associated with adrenal insufficiency: a distinct clinical entity. Leuk Lymphoma 1997; 24:363-7. [PMID: 9156667 DOI: 10.3109/10428199709039025] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We describe a case of a 42 year old male who presented with Addison's disease resulting from primary lymphoma of the adrenals. Our case and a review of the literature indicates that this distinct entity has some unique clinical and radiologic features. In this entity, the lymphoma tends to be extranodal and have a poor prognosis. In addition, the computed tomography (CT) images have the unique appearance of enlargement of the adrenal gland with maintenance of the adreniform shape. We suggest that primary adrenal lymphoma is a distinct clinical entity and should be considered in patients with an elevated serum lactate dehydrogenase, characteristic CT findings and Addison's disease.
Collapse
Affiliation(s)
- M Pimentel
- Department of Medicine, University of Manitoba, Winnipeg, Canada
| | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- Y Matsumoto
- Department of Dermatology, Nagoya University School of Medicine, Japan
| | | | | | | |
Collapse
|
30
|
Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. CRITICAL REVIEWS IN ORAL BIOLOGY AND MEDICINE : AN OFFICIAL PUBLICATION OF THE AMERICAN ASSOCIATION OF ORAL BIOLOGISTS 1996; 7:144-58. [PMID: 8875029 DOI: 10.1177/10454411960070020301] [Citation(s) in RCA: 81] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Sjögren's syndrome is a systemic autoimmune disorder characterized by symptoms of oral and ocular dryness and a chronic, progressive loss of salivary and lacrimal function. The exocrine involvement is the result of a focal, peri-ductal mononuclear cell infiltrate and the subsequent loss of secretory epithelial cells. The mechanisms of this autoimmune exocrinopathy are not understood fully. Many recent investigations have described alterations in a number of immune mediators within the salivary glands. These studies provide new insights into the immune regulation of normal salivary gland functions and the mechanisms of gland damage in Sjögren's syndrome.
Collapse
Affiliation(s)
- P C Fox
- Clinical Investigations and Patient Care Branch, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892-1190, USA
| | | |
Collapse
|
31
|
Kauppi MJ, Savolainen HA, Anttila VJ, Isomäki HA. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996; 85:248-50. [PMID: 8640061 DOI: 10.1111/j.1651-2227.1996.tb14004.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Two cases of acute leukaemia have developed in a group of 77 patients treated with chlorambucil (Chl) because of severe juvenile chronic arthritis. The total follow-up from the beginning of Chl treatment in these patients was 560 years, indicating a highly increased risk of leukaemia. Despite favourable results, especially in patients with secondary amyloidosis, Chl should only be used in selected cases.
Collapse
Affiliation(s)
- M J Kauppi
- Rheumatism Foundation Hospital, Heinola, Finland
| | | | | | | |
Collapse
|
32
|
Semple JW, Freedman J. Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfus Med Rev 1995; 9:327-38. [PMID: 8541715 DOI: 10.1016/s0887-7963(05)80080-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
MESH Headings
- Animals
- Antibody Specificity
- Antigens, Human Platelet/immunology
- Autoantibodies/immunology
- Autoantigens/immunology
- Autoimmune Diseases/immunology
- Autoimmune Diseases/therapy
- Blood Platelets/immunology
- Cytokines/physiology
- Disease Models, Animal
- Disease Susceptibility/immunology
- Genetic Predisposition to Disease
- HLA Antigens/genetics
- HLA Antigens/immunology
- Humans
- Immunity, Cellular
- Leukemia, Lymphoid/immunology
- Lymphocyte Subsets/immunology
- Lymphocyte Subsets/pathology
- Male
- Mice
- Mice, Inbred Strains
- Mice, Mutant Strains
- Platelet Membrane Glycoproteins/immunology
- Purpura, Thrombocytopenic, Idiopathic/immunology
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Rats
Collapse
Affiliation(s)
- J W Semple
- Division of Hematology, St. Michael's Hospital, Toronto, Ontario, Canada
| | | |
Collapse
|
33
|
Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995; 99:276-81. [PMID: 7653488 DOI: 10.1016/s0002-9343(99)80160-0] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
PURPOSE To evaluate the relationship between use of methotrexate in rheumatoid arthritis patients and development of hematologic malignancies. PATIENTS AND METHODS We retrospectively analyzed all patients registered at the Mayo Clinic from 1976 through 1992 with rheumatoid arthritis (n = 16,263) cross-indexed with patients registered during the same period with a hematologic malignancy (n = 21,270). Adult patients were selected who had rheumatoid arthritis, were treated with a disease-modifying antirheumatic drug, and subsequently developed a hematologic malignancy. RESULTS Thirty-nine patients met the selection criteria. Twelve of them had been given methotrexate. The characteristics of those who received methotrexate, including the type of hematologic malignancy, did not differ from those of patients who received other disease-modifying antirheumatic drugs. CONCLUSIONS Hematologic malignancies are uncommon in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs, including methotrexate. There does not appear to be a relationship between the peak or cumulative dose or the duration of methotrexate therapy and the subsequent development of hematologic malignancy. The histologic types of hematologic malignancy seen in the methotrexate-treated patients did not differ from those of patients treated with other disease-modifying antirheumatic drugs.
Collapse
Affiliation(s)
- K G Moder
- Division of Rheumatology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
| | | | | | | | | |
Collapse
|
34
|
Guo K, Major G, Foster H, Bassendine M, Collier J, Ross D, Griffiths I. Defective repair of O6-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma. Ann Rheum Dis 1995; 54:229-32. [PMID: 7748022 PMCID: PMC1005562 DOI: 10.1136/ard.54.3.229] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE To investigate a role for mutation in the aetiogenesis of autoimmune disease by examining levels of repairing enzyme for the promutagenic DNA base lesion, O6-methylguanine, in lymphocyte extracts from patients with autoimmune diseases. We included primary Sjögrens syndrome (PSS) patients because of the additional relevance of their being at increased risk (> 40-fold) of developing lymphoma. METHODS Lymphocytes were prepared from patients with PSS (n = 22) (12 with parotid gland enlargement, an indicator of extensive lymphoproliferation), rheumatoid arthritis (n = 12), primary biliary cirrhosis (n = 11), osteoarthritis (n = 12), and healthy individuals (n = 11). MGMT amounts were determined in lymphocyte extracts by direct enzyme assay and expressed in relation to total extract DNA, protein, or cell number. RESULTS We found no defect in the repairing methyltransferase enzyme between any of the groups, except in PSS patients at increased risk of developing lymphoma (those with enlarged parotid glands): p < 0.0001 and p = 0.0056, compared with healthy controls and PSS patients without parotid gland swelling, respectively. CONCLUSIONS Our findings implicate persistence of O6-methylguanine-DNA in the aetiology of lymphoma associated with PSS, and raise the possibility that an alternative repair process for O6-methylguanine-DNA, nucleotide excision repair, might be defective in autoimmune disease.
Collapse
Affiliation(s)
- K Guo
- Department of Medicine (Medical Molecular Biology Group), Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- P G Isaacson
- Department of Histopathology, University College London Medical School, UK
| | | |
Collapse
|
36
|
Berczi I, Baragar FD, Chalmers IM, Keystone EC, Nagy E, Warrington RJ. Hormones in self tolerance and autoimmunity: a role in the pathogenesis of rheumatoid arthritis? Autoimmunity 1993; 16:45-56. [PMID: 8136466 DOI: 10.3109/08916939309010647] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Recent studies indicate that pituitary hormones play an important role in immunoregulation. The evidence that endocrine abnormalities are associated with, and may contribute to the development of autoimmune disease is reviewed and discussed. Patients suffering from rheumatoid arthritis show a number of endocrine abnormalities that indicate altered pituitary function. The decreased bioactivity of prolactin and possible inadequate glucocorticoid response to inflammation found in patients may have an etiological role in rheumatoid arthritis. The further clarification of the possible role of endocrine factors in the etiology of autoimmune disease is needed urgently.
Collapse
Affiliation(s)
- I Berczi
- Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
| | | | | | | | | | | |
Collapse
|